What is the Purpose of this Study?
2.1 Primary Objectives 2.1.1 To assess the effect size of a 6-week Photobiomodulation intervention has on cognitive symptoms in cancer patients with cancer-related cognitive impairment, as measured by changes in scores on the PROMIS Cognitive Function-Short-Form 8a 2.2 Secondary Objectives 2.2.1 To assess the impact a 6-week Photobiomodulation intervention has on cognitive abilities in cancer survivors 2.2.2 To assess the impact a 6-week Photobiomodulation intervention has on quality of life in cancer survivors 2.2.3 To assess the impact a 6-week Photobiomodulation intervention has on depression in cancer survivors 2.2.4 To assess the impact a 6-week Photobiomodulation intervention has on anxiety in cancer survivors 2.3 Exploratory Objectives 2.3.1 To assess the feasibility of a 6-week Photobiomodulation intervention 2.3.2 To assess the feasibility of completely surveys at 3 research visits throughout the study
Eligibility
- * Adults ≥ 18 years
- * Previous diagnosis of stage I-III non-central nervous system solid tumor malignancy, Hodgkin, or Non-Hodgkin lymphoma
- * Completed cancer treatment (chemotherapy and/or radiation) more than 6 months ago but less than 5 years ago (Current concurrent endocrine therapy, anti-HER-2 therapy allowed, or other stable maintenance therapies (such as rituximab) will be allowed.
- * Self-reported cognitive complaints (score ≤ 54 on the Functional Assessment of Cancer Therapy-Cognition, Version 3, Perceived Cognitive Impairment subscale)
Where can I participate?
CS Cancer at Cedars-Sinai Medical Center : Ana Martin
More about this Clinical Trial
What is the full name of this clinical trial?
IIT2022-14-ASHER-HELMET: Pilot Study of Photobiomodulation for Cancer-Related Cognitive Impairment